LCS
HOWL icon

Levin Capital Strategies’s Werewolf Therapeutics HOWL Stock Holding History

Levin Capital Strategies’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$74K – 199
2024
Q4 		$74K Buy
+50,000
New +$102K 0.01% 211
2021
Q4 		– Sell
-15,000
Closed -$257K – 366
2021
Q3 		$257K Buy
+15,000
New +$256K 0.03% 250

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Levin Capital Strategies's HOWL Position: Q1 2025 in Review

Levin Capital Strategies sold out of Werewolf Therapeutics (HOWL) in Q1 2025, closing a stake of 50,000 shares — an estimated $74K sold.

Levin Capital Strategies first reported a position in HOWL in Q3 2021 and held it in 2 quarters. The position peaked at $257K in Q3 2021. 70 funds tracked by Wall St. Rank hold HOWL as of Q1 2025.

  • Levin Capital Strategies reported no remaining Werewolf Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Levin Capital Strategies sold 50,000 Werewolf Therapeutics shares in Q1 2025, an estimated $74K.
  • Levin Capital Strategies first reported a position in Werewolf Therapeutics in Q3 2021 and held it in 2 quarters.
  • Levin Capital Strategies's Werewolf Therapeutics position peaked at $257K in Q3 2021.
  • 70 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2025.

Based on Levin Capital Strategies's 13F filing for Q1 2025, filed 9 May 2025.